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The National Toxicology Program (NTP) is
responsible for evaluating the toxicity and car-
cinogenicity of environmental agents, develop-
ing and validating improved testing methods,
and strengthening the science base of toxicol-
ogy. A variety of end points are used to assess
the systemic toxicity of environmental chemi-
cals, but the mainstay of chemical carcino-
genicity testing has been the 2-year rodent
bioassay. This highly standardized method has
been widely adopted throughout the world.
However, like any other approach, the rodent
bioassay has its strengths and weaknesses. In
particular, the 2-year bioassay is expensive,
both in resources and time required and in the
numbers of animals needed. Thus, the advent
of transgenic and gene knockout technology in
the early 1980s and increasing knowledge of
the mechanisms involved in carcinogenesis led
a number of investigators to examine whether
faster, less costly, and more predictive models
might be developed. The National Institute of
Environmental Health Sciences (NIEHS) has
been actively involved in this effort for more
than a decade, and several model systems using
transgenic and knockout models have been
investigated (Bucher 1998; Eastin et al. 1998;
Tennant 1993; Tennant et al. 1995).
Transgenic models have a number of
potential advantages for use in carcinogen
identiﬁcation programs. For example, because
tumors arise more quickly in the genetically
engineered models, the assays can be more
rapid. For the studies reviewed here, the assay
length was 24–26 weeks, signiﬁcantly shorter
than the standard 2-year rodent bioassay.
Transgenic models may also provide the
opportunity to reduce the number of animals
used in testing. Shorter assays using fewer
animals could also reduce the overall cost of
testing programs. However, proprietary issues
and the limited availability of some models
may impact cost savings. Furthermore, with
appropriate model selection, it may become
possible to more accurately predict the human
response, contributing directly to the ease and
effectiveness of risk assessment and regulatory
decisions. Finally, by virtue of the specific
genetic modiﬁcation(s) in transgenic models, it
should be possible to gain additional insights
into the mechanisms involved in tumor induc-
tion and development. Such insights would
facilitate identification of important mecha-
nisms of the tumor response and chemical fea-
tures associated with carcinogenesis.
Although they have great promise, trans-
genic models also have actual or potential
limitations for use in a carcinogen identiﬁca-
tion effort. For example, many current trans-
genic models (including those evaluated here)
have mutations in only one pathway that may
or may not be relevant to human cancer
processes for a given chemical. In addition,
the speciﬁc gene defect may inﬂuence tumor
development and type, increasing the difﬁculty
of modeling the human response. Likewise,
the strain (genetic) background can inﬂuence
tumor type, incidence, and location. Thus,
short-term, gene-specific transgenic assays
may lose biological information obtained in
longer term bioassays (e.g., multiple target
organ effects and/or interactions of time and
age that are important in chemical carcino-
genicity). These issues do not preclude the use
of transgenic models, but they must certainly
be considered in their development and selec-
tion and in interpretation of data obtained
using transgenic models.
Given the potential and the limitations of
the transgenic models, the goals of the current
assessment were to a) review progress in this
field of research, b) determine if the models
reviewed show sufﬁcient merit for use in a car-
cinogen identiﬁcation program, and c) identify
research needs and knowledge gaps that should
be addressed to increase the effectiveness of
transgenic models.
Review of Research Progress
Many transgenic models are available for vari-
ous investigational uses, but three transgenic
models have been most widely used for car-
cinogen identiﬁcation: Trp53+/–, Tg.AC, and
RasH2. We selected these three models for this
assessment because they have the extensive
data set needed for this analysis. Their selec-
tion does not indicate that they are deemed
superior a priori to other transgenic models.
Extensive recent reviews of these three
models have been published, and only their
main features are brieﬂy reviewed here. They
were developed based on dysregulation of either
the Trp53 tumor-suppressor gene or the ras-
proto-oncogene, both of which are critical to
cancer development and which represent the
two main classes of human cancer genes. The
p53 protein suppresses cancer in humans and
rodents and is mutated or dysfunctional in
more than 50% of all cancers (Donehower et
al. 1992; Hollstein et al. 1991; Weinberg
1991a). As a transcription factor, p53 regulates
the activity of a variety of genes involved in cell
cycle arrest, apoptosis, anti-angiogenesis, differ-
entiation, DNA repair, and genomic stability
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In this article, we examine existing data on the use of transgenic mouse models for identiﬁcation
of human carcinogens. We focus on the three most extensively studied of these mice, Trp53+/–,
Tg/AC, and RasH2, and compare their performance with the traditional 2-year rodent bioassay.
Data on 99 chemicals were evaluated. Using the International Agency for Research on
Cancer/Report on Carcinogens determinations for the carcinogenicity of these chemicals to
humans as the standard for comparison, we evaluated a variety of potential testing strategies rang-
ing from individual transgenic models to combinations of these three models with each other and
with traditional rodent assays. The individual transgenic models made the “correct” determina-
tions (positive for carcinogens; negative for noncarcinogens) for 74–81% of the chemicals, with an
increase to as much as 83% using combined strategies (e.g., Trp53+/– for genotoxic chemicals and
RasH2 for all chemicals). For comparison, identical analysis of chemicals in this data set that were
tested in the 2-year, two-species rodent bioassay yielded correct determinations for 69% of the
chemicals. However, although the transgenic models had a high percentage of correct determina-
tions, they did miss a number of known or probable human carcinogens, whereas the bioassay
missed none of these chemicals. Therefore, we also evaluated mixed strategies using transgenic
models and the rat bioassay. These strategies yielded approximately 85% correct determinations,
missed no carcinogens, and cut the number of positive determinations for human noncarcinogens
in half. Overall, the transgenic models performed well, but important issues of validation and
standardization need further attention to permit their regulatory acceptance and use in human risk
assessment. Key words: carcinogens, hazard identification, mouse model, mutagenesis screening,
transgenic models. Environ Health Perspect 111:444–454 (2003). doi:10.1289/ehp.5778 available
via http://dx.doi.org/ [Online 30 October 2002]
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proto-oncogene protein (H-, K-, and N-ras
isoforms) is integral to cell proliferation
through signaling by growth factors and nox-
ious agents (chemicals, UV radiation, etc.) that
act via the mitogen-activated protein kinase
kinase (MAPKK) pathway (Campbell et al.
1998; Gupta et al. 2000; Pruitt and Der
2001). Activation and dysregulation of ras
through mutations at speciﬁc sites within the
gene are often observed in both human and
rodent cancers (Bos 1989; Hruban et al. 1993;
Vogelstein et al. 1990; Yunis et al. 1989). In
addition, increased expression of oncogenic ras
protein is often seen during tumorigenesis by
aneuploidy of the ras-bearing chromosomes,
which may be analogous to overexpression of
induced transgenic ras protein. Overall, ras is
overexpressed in more than 50% of all cancers.
The Trp53 heterozygous null allele (+/–)
mouse. This model uses B6129 N5 mice
heterozygous for a wild-type Trp53 tumor-
suppressor gene and a null allele that is not
transcribed or translated (Donehower et al.
1992; Harvey et al. 1993). These Trp53
heterozygotes (+/–) have a low spontaneous
tumor incidence up to 9 months of age but
have increased spontaneous tumor rates there-
after with approximately 50% survival at 18
months. Therefore, short-term (26 week)
exposure to test and positive control agents
during the period between 7 and 33 weeks of
age makes it possible to distinguish between
treatment-induced and spontaneous tumors
that may arise independently and confound a
cancer bioassay (Haseman and Elwell 1996;
Karstadt and Haseman 1997). The Trp53
model appears to be particularly useful as an
in vivo test for mutagenic carcinogens
(Donehower et al. 1992; Eastin et al. 1998;
Harvey et al. 1993; Kemp et al. 1993, 1994;
Tennant et al. 1995). In human cancers, where
mutations have been found in up to 50% of all
tumors (Greenblatt et al. 1994; Hollstein et al.
1991), point mutations or deletions in one
allele of the Trp53 gene that create a heterozy-
gous allelic state are usually accompanied by
loss of the normal allele (loss of heterozygosity
or LOH) (Weinberg 1991b). Because Trp53
+/– mice only carry one copy (germline) of the
gene, these mice were expected, according to
the two-hit hypothesis (Knudson 1996;
Knudson et al. 1975), to show a shorter
latency period for tumors induced by geno-
toxic agents. However, there is evidence that
the acceleration of tumorigenesis in Trp53+/–
mice may be due to a gene dosage effect and a
haplo-insufﬁcient phenotype such that a sec-
ond (p53 LOH) event is not required (French
et al. 2001; Venkatachalam et al. 1998).
The Tg.AC (v-Ha-ras) mouse. The Tg.AC
transgenic mouse model provides a reporter
phenotype (skin papillomas) in response to
either genotoxic or nongenotoxic carcinogens,
including tumor promoters (Spalding et al.
1993, 1999; Tennant et al. 1999). Tg.AC mice
are hemizygous for a mutant v-Ha-ras trans-
gene. The model was developed by Leder et al.
(1990), with an inducible ζ-globin promoter
driving the expression of a mutated v-Ha-ras
oncogene and is regarded as a genetically initi-
ated model. With the exception of the bone
marrow, constitutive expression of the trans-
gene cannot be detected in adult tissues. The
transgene is transcriptionally silent until acti-
vated by full-thickness wounding, UV irradia-
tion, or speciﬁc chemical exposure (Cannon et
al. 1997; Trempus et al. 1998). Topical appli-
cation of carcinogens to the shaved dorsal sur-
face of Tg.AC mice induces epidermal
squamous cell papillomas or carcinomas, a
reporter phenotype that deﬁnes the activity of
the chemical. The oral route of administration
can also generate tumor responses in the skin
of Tg.AC mice and in addition lead to squa-
mous cell papillomas and/or carcinomas of the
forestomach. To date, the appearance of either
spontaneous or induced tumors has been
shown to require activation of transgene
expression. However, the mechanism of
response by the Tg.AC model to chemical car-
cinogens is not yet understood.
The rasH2 mouse. The rasH2 mouse is
hemizygous for the human c-Ha-ras transgene
under control of its endogenous promoter
and enhancer sequences. It was developed by
Saitoh et al. (1990) in CB6F1 mice to evalu-
ate the association of chemically induced
transgene expression and tumor induction
(Katsuki et al. 1991; Yamamoto et al. 1996,
1998a). The transgene encodes a prototype c-
H-ras gene product, p21, that does not
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Table 1. Comparison of results from 14 known human carcinogens tested in rodent NCI/NTP cancer bioassays, Salmonella (Sal) and/or in vivo micronuclei (Mn)
genotoxicity assays, and/or three transgenic mouse cancer bioassays.
CAS IARC NTP NCI/NTP Genotoxicity
Agent no. group ROC bioassays (Sal;  Mn) p53  +/– Tg.AC RasH2
Benzene 71-43-2  1  Known +; +; +; +g –; + +g; +g (French et al. 2001)  +d; +g (Blanchard et al. 1998;  +g (Yamamoto et al. 1998b)
(NTP 1986a) –g; –g (Storer et al. 2001) Spalding et al. 1999)
Cyclophosphamide 6055-19-2 1  Known +; +; +; +ip +; + +g (Storer et al. 2001) ±d; +g (Eastin et al. 2001) ±g; +g; 
(Weisburger 1977) +g (Usui et al. 2001; 
Yamamoto et al. 1998b)
Melphalan 148-82-3 1 Known +; +; +; +ip  +; + +ip (Eastin et al. 1998;  ±d; +g (Eastin et al. 1998;  ±ip (Yamamoto et al. 1998b)
(Weisburger 1977) Storer et al. 2001) 2001)
Cyclosporin A 79217-60-0  1 Known NT –; – –g; +f; +f (Eastin et al. 1998;  +d; ±f (Eastin et al. 1998;  ±g (Maronpot et al. 2000; 
Storer et al. 2001) 2001) Usui et al. 2001; 
Yamamoto et al. 1998a)
Diethylstilbestrol 56-53-1 1 Known NT –; NT –sc; +f (Eastin et al. 1998;  +d; –g (Eastin et al. 1998;  +f (Usui et al. 2001)
Storer et al. 2001) 2001)
17β-Estradiola 50-28-2 1  Reasonable NT –; – ±g; –g (Storer et al. 2001) +d; –g (Eastin et al. 2001) –g (Usui et al. 2001)
TCDDb 1746-01-6  1  Known +; +; +; +f  –; NT –g (Eastin et al. 1998) +d (Eastin et al. 1998) NT
(NCI/NTP 1982a)
UVR (312–450 nM) NA 1 Known NT +; + +d (Jiang et al. 1999) +d (Trempus et al. 1998) NT
Asbestos ﬁbers 1332-21-4 1  Known –; –; NT; NT f  NT; – +ip (Marsella et al. 1997) NT NT
(NTP 1988a)
Beryllium 7440-41-7 1  Known NT –; – +I (Finch et al. 1998)  NT NT
Plutonium-239  NA 1 Known NT +; + +I (Finch et al. 1998) NT NT
Cobalt-60 (LET)  NA 1  Known NT –; + +wb (Kemp et al. 1994) NT NT
Sodium arsenate 7784-46-5 1 Known NT NT; NT NT –d (Germolic et al. 1997) NT
Thio-TEPA 52-24-4  1  Known +; +; +; +g +; NT NT NT +ip (Yamamoto et al. 1998b)
(NCI/NTP 1978a)
Abbreviations: –, negative; +, positive; ±, equivocal; d, dermal; f, food; g, gavage; I, inhalation; ip, intraperitoneal; LET, linear energy transfer; NT, not tested or no published record; sc,
subcutaneous; wb, whole body. Individual results were found in the cited references or in the IARC (2002) or the NTP databases (NTP 2002). NCI/NTP peer-reviewed conclusions are
reported for male rat, female rat, male mouse, and female mouse, respectively. Results from transgenic models are presented as the summary conclusion for each route of exposure
using one or both sexes of the strain used. 
aBoth dermal and gavage studies in the Tg.AC mice employed ethinyl estradiol (CAS no. 57-63-6), a synthetic form of 17β-estradiol. b2,3,7,8-Tetrachlorodibenzo-p-dioxin.induce transformation in NIH3T3 cells.
Approximately three copies of the human
transgene were integrated into the mouse
genome in a tandem array through pronuclear
injection (Suemizu et al. 2002). Expression of
the transgenic protein is observed in normal
tissues and increased approximately 2-fold in
chemically induced tumors (Maruyama et al.
2001). Mutation of the endogenous mouse ras
genes or of the transgene is infrequent and
unpredictable (Katsuki et al. 1991), suggesting
that a 2- to 3-fold increase in ras protein
expression is sufﬁcient to cooperate with other
carcinogen-induced changes (genetic and/or
epigenetic) to predispose this mouse to devel-
opment of neoplasia.
Merits of the Models
Data collection. To assess the potential merit
of the three transgenic models in a research
and testing program, we assembled available
information on responses to chemical treat-
ment in each model (Tables 1–3). The pri-
mary sources of these data were the recent
publications of the International Life Sciences
Institute (ILSI) Assay Working Groups for
the Trp53+/–, Tg.AC, and RasH2 Mouse
Alternative Models (Popp 2001; Robinson
and MacDonald 2001), NTP evaluations,
and published independent laboratory
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Table 2. Comparison of results from 32 suspected human carcinogens tested in rodent NCI/NTP cancer bioassays, Salmonella (Sal) and/or in vivo micronuclei
(MN) genotoxicity assays, and/or three transgenic mouse bioassays.
IARC NCI/NTP Genotoxicity
Agent CAS no.  group ROC bioassays (Sal; Mn) p53+/– Tg.AC RasH2
p-Cresidine 120-71-8  2B  Reasonable +; +; +; +f +; – +f; +g (Storer et al. 2001;  +d (Tennant et al. 1999) +f (Yamamoto et al. 1998b)
(NCI/NTP 1979a) Tennant et al. 1995)
Glycidol 556-52-5  2A  Reasonable +; +; +; +g +; + –g (Tennant et al. 1999) –d; –g (Tennant et al. 1999) +g (Usui et al. 2001)
(NTP 1990a)
Phenolphthalein 77-09-8 2B  Reasonable +; +; +; +f –; + +f NT –f (Koujitani et al. 2000)
(NTP 1996a) (Dunnick et al. 1997)
4-Vinyl-1-cyclohexene 106-87-6 2B  Reasonable +; +; +; +d  +; + +d (Tennant et al. 1995) –d (Tennant et al. 1999) +d (Yamamoto et al. 1998b)
diepoxide (NTP 1989a)
2,4-Diaminotolulene 95-80-7 2B Reasonable +; +; –; +f  +; – ±f (Eastin et al. 1998) +d (Eastin et al. 1998) NT
(NCI/NTP 1979b)
Chloroprene 126-99-8  2B  Reasonable +; +; +; +I –; – –i (French. Personal  –i (French. Personal  NT
(NTP 1998a) communication) communication)
Pentachlorophenol 87-86-5 2B Not  listed +a; –; +; +f –; – –f (Spalding et al. 2000) +d (Spalding et al. 2000) NT
(NTP 1989b, 1999a)
Phenacetin 62-44-2 2A  Reasonable NT –; NT –f; –g (Storer et al. 2001) –d; –f (Eastin et al. 2001) +f (Yamamoto et al. 1998b) 
Phenobarbital 50-06-6 2B  Not listed NT wk+; NT –f; –f (Sagartz et al. 1998;  ia d; ia g; ia f  –g (Usui et al. 2001) 
Storer et al. 2001) (Eastin et al. 2001)
Chloroform 67-66-3 2B  Reasonable +; –; +; +w –; + ±g (Storer et al. 2001) –g (Delker et al. 1999) –g (Usui et al. 2001)
(Griesemer and 
Cueto 1980)
Benzo[a]pyrene 50-32-8 2A  Reasonable NT +; NT +d, g (Martin et al. 2001) +d (Martin et al. 2001) NT
Dimethylnitrosamine  62-75-9  2A  Not listed NT +; NT +w (Harvey et al. 1993) NT NT
7,12-Dimethylbenzanthraceneb 57-97-6 NE  Not listed NT; NT; +; +d,  +; + +d (Kemp et al. 1993) +d (Spalding et al. 1993) NT
i-p (NTP 1996b) 
N-Ethyl-N-nitrosourea  759-73-9  2A  Not listed NT +; + +ip (Mitsumori et al. 2000) NT +ip (Yamamoto et al. 1998b)
2-Amino-3-methyl 76180-96-6  2A  Not listed NT +; + +g (Morimura 1999) NT NT
imidazo[4,5-f]quinoline
N-Butyl-N-(4-hydroxybutyl) 64091-91-4 2B  Not listed NT NT; – +w (Ozaki et al. 1998) NT NT
nitrosamine (BBN)
N-Methyl-N-nitrosourea 684-93-5 2A  Not listed NT NT; + +ip (Yamamoto et al. 2000) NT +ip (Yamamoto et al. 1998b)
Urethane 51-79-6 2B  Reasonable NT +; + +ip (Carmichael et al. 2000) +d (Spalding et al. 1993) +ip (Mori et al. 2000; 
Umemura et al. 1999)
Oxymetholone 434-07-1  2A Reasonable ±; +; NT; NT  –; – –g (Stoll et al. 1999) +d (Stoll et al. 1999) NT
(NTP 1999b)
1, 2-Dimethylhydrazine 540-73-8 2A Not listed NT –c; NT NT NT +d (Yamamoto et al. 1998b)
1,4-Dioxane 123-91-1 2B Reasonable +; +; +; +w –; + NT NT ±w (Yamamoto et al. 1998b)
(NCI/NTP 1978b)
Ethylene thiourea 96-45-7  2B  Reasonable +; +; +; +f  –; NT NT NT +f (Yamamoto et al. 1998b)
(NTP 1992a)
Methylazoxymethanol acetate 592-62-1 2B  Not listed NT –; NT NT NT +sc (Yamamoto et al. 1998b)
Procarbazine 366-70-1 2A  Reasonable +; +; +; +ip +; + NT NT +ip (Yamamoto et al. 1998b) 
(NCI/NTP 1979c)
4,4´-Thiodianiline 139-65-1 2B  Not listed +; +; +; +f  +; NT NT NT +f (Yamamoto et al. 1998b)
(NCI/NTP 1978c)
MNNG 70-25-7 2A Reasonable +; +; +d ip  +; NT NT NT +g (Yamamoto et al. 1998b)
(NTP 1996b)
Cupferron 135-20-6 2A Reasonable +; +; +; +f  +; NT NT NT +f (Yamamoto et al. 1998b)
(NCI/NTP 1978d)
N-Nitrosodiethylamine 55-18-5 2A Reasonable NT +; NT NT NT +ip (Yamamoto et al. 1998b)
Dimethylvinylchloride 513-37-1 2B Not listed +; +; +; +g +; + NT +d (Stoll et al. 1999) NT
(NTP 1986b)
4-Nitroquinoline N-oxided 56-57-5 NE Not listed NT +; NT NT NT +sc (Yamamoto et al. 1998b)
4-Hydroxyaminoquinoline-1-oxided 4637-56-3  NE Not listed NT +; NT NT NT +ip (Yamamoto et al. 1998b)
Mirex 2385-85-5 2B Reasonable +; +; NT; NT f –; NT NT +d (Stoll et al. 1999) NT 
(NTP 1990b)
Abbreviations: –, negative; +, positive; ±, equivocal; d, dermal; f, food; g, gavage; I, inhalation; ia, inadequately evaluated; ip, intraperitoneal; i-p, initiation–promotion; MNNG, N-methyl-
N'-nitro-N-nitrosoguanidine; NE, not evaluated; NT, not tested or no published record; sc, subcutaneous; w, drinking water; wk, weakly. Individual results are found in the cited refer-
ences or in the IARC (2002) or the NTP databases (NTP 2002). NCI/NTP peer-reviewed conclusions are reported for male F344 rat, female F344 rat, male B6C3F1 mouse, and female
B6C3F1 mouse, respectively. Results from transgenic models are presented as the summary conclusion for each route of exposure using one or both sexes.
aPositive in 1,000-ppm 1-year exposure stop study but not with 2-year exposure to puriﬁed pentachlorophenol at lower levels (NTP 1989b, 1999a). bReasonably anticipated to be a human
carcinogen based on its use as a prototypical mutagenic carcinogen in initiation-promotion and complete carcinogenicity studies. c1,2-Dimethylhydrazine dihydrochloride (CAS no.
306-37-6) tested in Salmonella mutagenicity assay. dReasonably expected to be a human carcinogen based upon its use as a prototypical mutagenic carcinogen for mechanistic investi-
gation of chemical carcinogenesis.research using alternative or conventional
rodent models for carcinogen identification
(for speciﬁc references, see Tables 1–3). The
resulting data set consists of 99 chemicals that
were tested at the maximum tolerated dose
(MTD) or proportional fractions of MTD as
determined by toxicokinetic and range-ﬁnd-
ing studies in the test strain using positive
and negative controls groups and nongeneti-
cally altered co-isogenic reference controls.
Dosing routes, study duration, number of ani-
mals per group, and extent of histopathologic
evaluation varied between studies and chemi-
cals. Despite these limitations, for the pur-
poses of this analysis, peer-reviewed published
ﬁndings were accepted as reported.
Criteria for analysis. Because the goal of
NTP carcinogenicity testing is prediction of
human carcinogenicity of chemicals, the merit
of each transgenic model was evaluated by
determining the ability of the model to iden-
tify human carcinogens. Classification of
human carcinogens was based on evaluations
by the NTP Report on Carcinogens (ROC)
(NTP 2002) and the International Agency for
Research on Cancer (IARC 2002) chemical
evaluations/classiﬁcations. Both the ROC and
IARC assessments are based on comprehensive
evaluations of all relevant human and animal
data from the published literature. The desig-
nation of an agent as a “known human car-
cinogen” by IARC (group 1) or the ROC
requires deﬁnitive data from human epidemi-
ologic studies or strong mechanistic data
from human systems in conjunction with
similar mechanistic and cancer data from
experimental animals. Less convincing evi-
dence (e.g., limited human data and/or sufﬁ-
cient animal data) will generally lead to the
designation of the agent as a “probable” (group
2A) or “possible” (group 2B) human carcino-
gen by IARC or a “reasonably anticipated”
human carcinogen in the ROC. A chemical
that shows inadequate evidence of carcino-
genicity in humans and animals will generally
result in an IARC designation of “not classiﬁ-
able” (group 3). The ROC has no equivalent
to IARC group 3 and does not list such chemi-
cals. Rodent carcinogenicity was not used as
the primary targeted response in our analysis.
Nevertheless, for completeness we did consider
the correlation of each transgenic model with
the outcomes of National Cancer Institute
(NCI)/NTP long-term rodent tests. We also
examined whether these transgenic assays were
more or less accurate in predicting human car-
cinogenicity of genotoxic versus nongenotoxic
chemicals, as deﬁned by either a positive result
in the Salmonella (Ames) test and/or in vivo
rodent micronucleus assay.
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Table 3. Comparison of results from 53 chemicals with insufficient evidence to be considered potential human carcinogens tested in rodent NCI/NTP cancer
bioassays, Salmonella (Sal) and/or in vivo micronuclei genotoxicity assays, and/or three transgenic mouse bioassays. 
IARC NCI/NTP Genotoxicity
Agent CAS no.  group ROC bioassays (Sal; Mn) p53+/– Tg.AC RasH2
p-Anisidine 90-04-0 3  Not listed ±; –; –; –f,  +; – –f (Tennant et al. 1995) –d (Tennant et al. 1995) –g (Maronpot et al. 2000)
(NCI/NTP 1978e)
1-Chloro-2-propanol 127-00-4  NE Not listed –; –; –; –w  +; NT –g (Tennant et al. 1999) –d (Tennant et al. 1999) NT
(NTP 1998b)
2,6-Diaminotoluene 820-40-5 NE Not listed –; –; –; –f  +; – –f (Eastin et al. 1998) –d (Eastin et al. 1998) NT
(Battershill and 
Fielder 1998)
8-Hydroxyquinoline 148-24-3 3 Not listed –; –; –; –f  +; – –f (Eastin et al. 1998) –d (Eastin et al. 1998) NT
(NTP 1985b)
Coconut oil diethanolamine 68603-42-9 NE Not listed –; ±; +; +d  –; + –d (Spalding et al. 2000) –d (Spalding et al. 2000) NT
(NTP 2001)
Diethanolamine 111-42-2 3 Not listed –; –; +; +d  –; – NT –d (Spalding et al. 2000) NT
(NTP 1999c)
Ethyl acrylate 140-88-5 2B Delisted +; +; +; +g  –; – NT –d (Nylander-French and  +g (Yamamoto et al. 1998b)
(NTP 1986c) French 1998; Tice et al. 1997)
Furfuryl alcohol 98-00-0 NE Not listed +; ±; +; –i  –; – NT –d (Spalding et al. 2000) NT
(NTP 1999d)
Lauric acid diethanolamine 120-40-1 NE Not listed –; –; –; +d  –; – –f (Spalding et al. 2000) +d (Spalding et al. 2000) NT
(NTP 1999e)
N-Methyloacrylamide 924-42-5 3 Not listed –; –; +; +g  –; – –g (Tennant et al. 1995) –d; –g (Eastin et al. 1998) NT
(NTP 1989c)
Methylphenidate  298-59-9  NE Not listed –; –; +; +f  –; NT –f (Tennant et al. 1999) –d (Tennant et al. 1999) NT
(NTP 1995a)
Pyridine 110-86-1 3  Not listed +; ±; +; +w  –; – –g (Spalding et al. 2000) –d (Spalding et al. 2000) NT
(NTP 2000)
Reserpine 50-55-5 3  Reasonable +; –:+; +f  –; – –f (Tennant et al. 1995) –d; –g (Tennant et al. 1995) –f (Yamamoto et al. 1998b)
(NCI/NTP 1982b)
Rotenone  83-79-4  NE Not listed ±; –; –; –f  –; NT –f (Eastin et al. 1998) +d; –g (Eastin et al. 1998) –g (Yamamoto et al. 1998b)
(NTP 1988b)
Resorcinol 108-46-3 3 Not listed –; –; –; –g  –; + –g (Eastin et al. 1998) +d (Eastin et al. 1998) –g (Maronpot et al. 2000)
(NTP 1992b)
Oleic acid diethanolamide 93-83-4 NE Not listed –; –; –; –d –; NT  –d (Spalding et al. 2000) –d (Spalding et al. 2000) NT 
(NTP 1999f)
Clolﬁbrate 637-07-0  3  Not listed NT –; – –g; –g (Storer et al. 2001) +d (Eastin et al. 2001) ±g; +g (Usui et al. 2001)
Dieldrin 60-57-1 3  Not listed –; –; ±; –f  –; NT –f (Storer et al. 2001) NT –f (Usui et al. 2001)
(NCI/NTP 1978f)
Methapyrilene HCl 135-23-9  NE Not listed +; +; NT; NT f –; – –g; –f (Storer et al. 2001) –d (Eastin et al. 2001) –g (Yamamoto et al. 1996)
(Lijinsky 1980)
Haloperidol 52-86-8 NE Not listed NT NT; NT –g (Storer et al. 2001) NT –g (Usui et al. 2001)
Chlorpromazine HCl 69-09-0  NE Not listed NT –; NT –g; –g (Storer et al. 2001) NT –g (Usui et al. 2001)
Metaproterenol 586-06-1 NE Not listed NT NT; NT –f; –f (Storer et al. 2001) NT –f (Yamamoto et al. 1998b)
WY-14643 50892-23-4 NE Not listed NT NT; NT –f (Storer et al. 2001) –d; ±f (Eastin et al. 2001) NT
Di(2-ethylhexyl)phthalate 117-81-7 3  Reasonable +; +; +; +f  –; – ±f (Storer et al. 2001) –d; –f (Eastin et al. 2001) +(Usui et al. 2001)
(NTP 1982c)
Sulfamethoxazole 723-46-6 3  Not listed NT –; NT –f (Storer et al. 2001) –d; –g (Eastin et al. 2001) –f (Usui et al. 2001)
Sulﬁsoxazole 127-69-5 3 Not listed –; –; –l; –f  –; NT –f (Storer et al. 2001) –d; –g (Eastin et al. 2001) –f (Usui et al. 2001)
(NCI/NTP 1979d)
Ampicillin 7177-48-2 3  Not listed ±; –; –; –f  –; NT –g (Storer et al. 2001) NT –g (Usui et al. 2001)
(NTP 1987)
Continued, next pageA total of 99 chemicals have been studied
in one or more of these three transgenic mod-
els. For this analysis, we divided these chemicals
into three groups: a) known human carcino-
gens (IARC group 1 and/or ROC known; 14
chemicals, Table 1); b) probable/possible
human carcinogens (IARC groups 2A and 2B
or ROC reasonably anticipated; 32 chemicals,
Table 2); and c) chemicals with inadequate evi-
dence of carcinogenicity (IARC group 3, NTP
bioassay negative, and/or not listed in the
ROC or by IARC; 53 chemicals, Table 3).
Tables 1–3 identify each chemical by
Chemical Abstracts Service (CAS) number
and give the IARC and/or the ROC evalua-
tions. For those chemicals evaluated in the
NTP rodent bioassay, carcinogenicity results
are given for each sex–species group (male
rats, female rats, male mice, female mice).
Genotoxicity outcomes from the Salmonella
(Ames) assay and the in vivo micronuclei
assays are also given. Finally, the results of
carcinogenicity testing in each of the three
transgenic models are given. The route of
administration is noted, as well as the pub-
lished reference source. For chemicals tested
more than once in the transgenic models,
each result is given separately.
For each of the transgenic models and for
the rodent bioassay, a chemical is designated as
a carcinogen if positive (carcinogenic) effects
were found in one or more of the sex–species
groups. Similarly, a chemical found to be posi-
tive in either the Salmonella assay or the in vivo
micronuclei assay is considered to be genotoxic.
Analysis of the models. Based on the 99-
chemical database from Tables 1–3, 10 possible
strategies were considered for using transgenic
models to identify chemicals as known or sus-
pected human carcinogens or as noncarcino-
gens. For comparison, the standard 2-year,
two-species rodent bioassay and a modified
strategy using the rat bioassay in conjunction
with genotoxicity were also analyzed in an
identical fashion. Thus, 12 strategies in all
were considered: 
• Strategy 1: Trp53+/– model
• Strategy 2: Trp53+/– model, but only for
genotoxic chemicals
• Strategy 3: Tg.AC model
• Strategy 4: RasH2 model
• Strategy 5: Trp53+/– model for genotoxic
chemicals; RasH2 model for nongenotoxic
chemicals
• Strategy 6: Trp53+/– model for genotoxic
chemicals; RasH2 model for all chemicals
• Strategy 7: Trp53+/– model for genotoxic
chemicals; Tg.AC model for nongenotoxic
chemicals
• Strategy 8: Trp53+/– model for genotoxic
chemicals; Tg.AC model for all chemicals
• Strategy 9: NTP bioassay
• Strategy10: NTP rat bioassay plus the
Tg.AC model for nongenotoxic chemicals or
the Trp53+/– model for genotoxic chemicals
• Strategy 11: NTP rat bioassay plus the
RasH2 model for nongenotoxic chemicals
or the Trp53+/– model for genotoxic
chemicals
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Table 3. Continued 
NCI/NTP Genotoxicity
Agent CAS No.  IARC NTP ROC bioassays (Sal; Mn) p53+/– Tg.AC RasH2
D-Mannitol 69-65-8 NE Not listed –; –; –; –f  –; – –f (Storer et al. 2001) NT –f (Yamamoto et al. 1998b)
(NCI/NTP 1982d)
1,1,2-Trichloroethane 79-00-5  3  Not listed –; –; +; +g  –; – NT NT –g (Yamamoto et al. 1998b)
(NCI/NTP 1978g)
Xylenes (mixed) 1330-20-7 3  Not listed –; –; –; –; –g  –; NT NT NT –g (Yamamoto et al. 1998b)
(NTP 1986d)
Furfural 98-01-1 3 Not listed +; –; +; +g –; NT NT NT +g (Yamamoto et al. 1998b)
(NTP 1990c)
5-Nitro-o-toluidine 99-55-8  3 Not listed –; –; +; +f +; NT NT NT +f (Yamamoto et al. 1998b)
(NCI/NTP 1978h)
Benzethonium chloride 121-54-0 NE  Not listed –; –; –; –d  –; NT NT –d (Spalding et al. 1999) NT
(NTP 1995b)
o-Benzyl-p-chlorophenol 120-32-1 NE  Not listed –; ±; +; –g –; NT NT +d (Spalding et al. 1999) NT
(NTP 1994)
2-Chloroethanol 107-07-3 NE  Not listed –; –; –; –d  +; – NT –d (Spalding et al. 1999) NT
(NTP 1985a)
Phenol 108-95-2 3 Not listed –; –; –; –dw –; + NT –d (Spalding et al. 1999) NT
(NCI/NTP 1980)
Triethanolamine 102-71-6 3 Not listed ±; –; ia; ia d  –; – NT –d (Spalding et al. 1999) NT
(NTP 1999g)
Acetic anhydride 108-24-7 NE Not listed NT –; NT NT –d (Spalding et al. 1999) NT
2,4-Dinitro-1-ﬂuorobenzene 70-34-8 NE Not listed NT +; NT NT +d (Albert et al. 1996) NT
Diisopropylcarbodiimide 693-13-0  NE Not listed In progress –; + In progress +d (Spalding et al. 1999) NT
Dicyclohexylcarbodiimide 538-75-0  NE Not listed In progress +; + NT –d (Spalding et al. 1999) NT
Fluocinolone acetonide 67-73-2 NE Not listed NT NT; NT NT –d (Albert et al. 1996) NT
Tripropylene glycol diacrylate 42978-66-5 NE Not listed NT –; – NT +d (Albert et al. 1996) NT
D-Limonene 5989-27-5  3  Not listed +; –; –; –f –; NT –g (Carmichael et al. 2000) NT NT
(NTP 1990d)
Foreign body (transponder) NA NE  Not listed NT –; – +sc (Blanchard et al. 1999) –sc (French J. Personal  NT
communication)
Acetone 67-64-1 NE Not listed NT –; – NT –d (Spalding et al. 1999;  NT
Spalding et al. 1993)
Benzoyl peroxide 94-36-0 3 Not listed +i-p –; NT NT +d (Spalding et al. 1993) NT
(NTP 1996b)
Ethanol 64-17-5 NE Not listed In progress –; NT NT –d (Spalding et al. 1999) NT
Methyl ethyl ketone peroxide 1338-23-4 NE Not listed In progress +; – NT +d (Spalding et al. 1993) NT
4-Nitro-o-phenylenediamine 99-56-9 3 Not listed –; –; –; –f  +; ± NT NT ±f (Yamamoto et al. 1998b)
(NCI/NTP 1979e)
6-Nitrobenzimidazole 94-52-0 NE Not listed –; –; +; +f  +; NT NT NT –f (Yamamoto et al. 1998b)
(NCI/NTP 1979f)
Cholestyramine 11041-12-6 NE Not listed NT NT; NT NT NT –f (Yamamoto et al. 1998b)
Magnetic ﬁelds (60 mHz) NA NE Not listed –; –; –; –wb –; – –wb (McCormick et al. 1998) –wb (McCormick et al. 1998) NT
(NTP 1999h)
Abbreviations: –, negative; +, positive; ±, equivocal; d, dermal; f, food; g, gavage; I, inhalation; i-p, initiation–promotion; NE, not evaluated; NT, not tested; sc, subcutaneous; w, drinking
water; wb, whole body. Individual results are found in the cited references or in the IARC (2002) or the NTP databases (NTP 2002). NCI/NTP peer-reviewed conclusions are reported for
male F344 rat, female F344 rat, male B6C3F1 mouse, and female B6C3F1 mouse, respectively. Results from transgenic models are presented as the summary conclusion for each route of
exposure using one or both sexes.Articles | Transgenic models
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• Strategy 12: NTP rat bioassay plus geno-
toxicity.
When evaluating strategies that were con-
ditional on genotoxicity (strategies 5–8,
10–11), the following conventions were estab-
lished: a) a chemical was considered genotoxic
if either the Salmonella or in vivo micronuclei
assays were positive; b) a chemical was consid-
ered nongenotoxic only if both assays were
negative; and c) when a chemical’s genotoxic-
ity could not be determined deﬁnitively (i.e.,
negative in one assay and not tested in the
other), the chemical was excluded from the
analysis, unless the genotoxicity status of the
chemical had no impact on the transgenic
mouse result (i.e., both transgenic models
were positive or both were negative).
A valid transgenic rodent model should
successfully identify (test positive) the
IARC/ROC known or suspected human car-
cinogens listed in Tables 1 and 2. Likewise,
such a model should identify as noncarcino-
gens (test negative) those chemicals in Table 3
that were shown in NTP long-term bioassays
to be negative. Although many of the remain-
ing chemicals in Table 3 were positive in a
long-term rodent bioassay, these results were
not considered by the IARC and/or ROC to
be sufﬁciently convincing to merit the catego-
rization of the chemical as a known, possible,
probable, or reasonably anticipated human car-
cinogen. For these chemicals, it is uncertain if
the response of the transgenic models should
be positive or negative as carcinogens. Thus,
our initial analysis (Table 4) included only
those group 3 chemicals with negative results
in the NTP rodent bioassay. Table 5 examines
the same data set as Table 4 but considers each
IARC/ROC classiﬁcation separately to ensure
that pooling carcinogen groups in these analy-
ses did not lose important distinctions between
assay responses to strong or weak carcinogens.
In addition, as summarized in Table 6, we
have conducted a second analysis in which all
chemicals in Table 3 are regarded as human
noncarcinogens (i.e., we have assumed, for the
sake of direct comparison between transgenic
and traditional NTP bioassays, that more
extensive testing of these chemicals would
conﬁrm their lack of human carcinogenicity).
This assumption permits exactly the same cri-
teria to be applied to all strategies, transgenic
and traditional alike. Finally, although human
carcinogenicity was used as the targeted
response in our analysis, a similar analysis was
conducted in which the transgenic assay
responses were compared with the results of
the NTP bioassay (Table 7).
Results and Discussion
Scope of analysis. Before discussing the analysis,
it is critical to reiterate the precise limitations
and assumptions implicit in our analysis. First,
this evaluation was limited to those chemicals
with definitive published transgenic results
available at the time of our analysis. We recog-
nize that this is a dynamic field of research.
Thus, additional transgenic studies will
become available over time, and it is possible
that some chemicals listed in Tables 1–3 could
be reclassiﬁed after consideration of such new
data. However, we suggest that the analyses for
these 99 chemicals are sufﬁciently robust that
the addition, subtraction, and/or reassignment
of chemicals will not alter the conclusions, pro-
vided that uniform criteria are applied.
Second, optimal protocol designs for spe-
ciﬁc transgenic animal cancer bioassays have
not been identiﬁed and validated. Thus, the
study designs that form the basis of this eval-
uation may differ from each other with regard
to study duration, sample sizes, dose selection
strategy, number of doses, tissues examined,
methods of statistical analysis, historical con-
trols, and the use of positive and negative
controls.
Third, we made no interpretative deci-
sions ourselves in regard to study results. For
assessments of possible human cancer risk, we
relied on the authoritative judgments of IARC
and the ROC. Likewise, we accepted the
authors’ interpretations of the data. However,
there was uniformity of study design and
interpretation for a sizable number of the
studies involved in the International Life
Sciences Institute (ILSI) Alternatives to
Carcinogenicity Testing consortium. It was
beyond the scope of our analysis to reevaluate
and reinterpret each individual study.
Fourth, we acknowledge that a positive
transgenic study may reflect a wide range of
carcinogenic responses, with some positive
results being limited to a marginal increase in a
single tumor type in a single sex–species group,
while others reﬂect striking multisite, multisex,
carcinogenic effects. Although future refine-
ments in statistical evaluation may permit sub-
classiﬁcation and rank order documentation for
the various positive transgenic responses, we
have not attempted to do so at this stage in the
development of transgenic rodent bioassays.
Finally, we recognize that certain chemi-
cals listed in Table 3 may ultimately be shown
to be known or suspected human carcinogens,
especially those with positive rodent bioassay
results. However, our current state of knowl-
edge does not permit a higher classiﬁcation of
these chemicals. As noted below, the fre-
quency of positive transgenic results for Table
3 chemicals was essentially the same for those
chemicals that were evaluated by the IARC
(and assigned to category 3) and those that
were not yet evaluated and are thus unclassi-
ﬁed. This suggests that there are few, if any,
important human carcinogens among the
unclassiﬁed chemicals in Table 3.
Performance of strategies. The overall per-
formance of each transgenic strategy is sum-
marized in Table 4. With the caveat that data
on all chemicals were not available for each
model and thus, that the subset of chemicals
actually tested in each model may influence
the specific outcomes reported, each of the
three transgenic mouse models predicted
human carcinogenesis for 77–81% of the
chemicals studied in that model, ranging from
77% for the Trp53+/–, 77% for the Tg.AC,
and 81% for the RasH2. Use of the Trp53+/–
for only genotoxic chemicals increased its pre-
dictiveness to 84%. The combined strategies
Table 4. Summary performance of each strategy versus likely human cancer. 
Positive for Negative for Positive for Negative for Overall
Strategy carcinogens noncarcinogens noncarcinogens carcinogens accuracy
Trp53+/– 21 12 0 10 77% (33/43)
Trp53+/– (genotoxic) 16 5 0 4 84% (21/25)
Tg.AC 17 10 2 6 77% (27/35)
RasH2 21 9 0 7 81% (30/37)
Trp53+/– (genotoxic); RasH2 (nongenotoxic) 17 10 0 6 82% (27/33)
Trp53+/– (genotoxic); RasH2 (all) 30 7 0 4 90% (37/41)
Trp53+/– (genotoxic); Tg.AC (nongenotoxic) 21 8 0 6 83% (29/35)
Trp53+/– (genotoxic); Tg.AC for all 25 7 2 4 84% (32/38)
All chemicals in Tables 1 and 2 are included as human carcinogens, but only those chemicals in Table 3 with negative
NCI/NTP bioassay results are regarded as true human noncarcinogens. Deﬁnitions: positive for carcinogens, positive assay
results for IARC/ROC carcinogens; negative for noncarcinogens, negative assay results for IARC/ROC noncarcinogens; posi-
tive for noncarcinogens, positive assay results for IARC/ROC noncarcinogens; negative for carcinogens, negative assay
results for IARC/ROC carcinogens. 
Table 5. Proportion of positive responses in the three transgenic models as a function of the IARC classiﬁ-
cation of these 99 chemicals. 
IARC classiﬁcation Trp53+/– Tg.AC RasH2 Overall
Group 1 83% (10/12) 89% (8/9) 57% (4/7)a 79% (22/28)
Group 2A 62% (5/8) 50% (2/4) 100% (9/9) 76% (16/21)
Group 2Bb 55% (6/11) 64% (7/11) 69% (9/13) 63% (22/35)
Group 3 0% (0/13) 21% (3/14) 29% (4/14) 17% (7/41)
Not evaluated 7% (1/15) 29% (7/24) 0% (0/8) 17% (8/47)
aTwo of the three that were not positive were equivocal. bIncludes 7,12-dimethylbenzanthracene, 4-nitroquinoline
N-oxide, and 4-hydroxyaminoquinoline-1-oxide. that use more than one transgenic model
(strategies 5–8; as deﬁned above) were some-
what more predictive, ranging from 82 to
90%. The best strategy (Trp53+/– for geno-
toxic chemicals and RasH2 for all chemicals;
strategy 6) correctly predicted the human out-
come for 90% of the agents (Table 4).
Strategy 8 (Trp53+/– for genotoxic chemicals
and Tg.AC for all chemicals) was only slightly
less predictive (84%).
Our initial analysis (Table 4) deﬁned the
targeted population of human carcinogens as
the pool of chemicals from Tables 1 and 2, in
which IARC classiﬁcations ranged from 1 to
2B. A further breakdown of these chemicals is
shown in Table 5. Note that a) the transgenic
models (considered collectively) are more apt to
be positive for the more certain human carcino-
gens (IARC groups 1 and 2A) than for the less
certain human carcinogens (group 2B); b) there
is a striking difference in the proportion of pos-
itive transgenic responses between the 1/2A/2B
chemicals and the group 3 chemicals or those
not evaluated; and c) the IARC group 3 chemi-
cals and those not evaluated show a similar rate
of overall transgenic responses, indicating that
most of the unclassified chemicals listed in
Table 3 may be human noncarcinogens.
Our initial analysis (Table 4) was some-
what restrictive, in that it defined human
noncarcinogens as being only those chemicals
from Table 3 with negative NCI/NTP rodent
bioassay results. However, Table 5 suggests
that it is reasonable to expand this classiﬁca-
tion and regard all Table 3 chemicals as
human noncarcinogens. This analysis is sum-
marized in Table 6, which allows more direct
comparison of the performance of the trans-
genic models with the traditional NTP two-
species bioassay. Transgenic and traditional
testing strategies each show strengths and
weakness. These strengths and weaknesses dif-
fer. For the transgenic models, particularly the
RasH2 and the Trp53+/–, there are relatively
few positive ﬁndings for noncarcinogens (i.e.,
group 3 chemicals, either known negatives or
chemicals unlisted by IARC/ROC, that gave
evidence of carcinogenicity in the assay). In
fact, as shown in Table 4, RasH2 and
Trp53+/– have no positive results for non-
carcinogens if those group 3 chemicals that
lack a negative rat and mouse bioassay are
eliminated from the analysis (in effect, elimi-
nating those chemicals with greater uncer-
tainty as to their carcinogenic potential). The
Tg.AC model was more prone to this type of
error than the other two transgenic models
reviewed (Tables 4 and 6). The combined
transgenic strategies (strategies 5–8) did not
improve predictability.
A more frequent shortcoming of the trans-
genic models (including those strategies using
multiple transgenic models) was the number of
negative tests for known or suspected human
carcinogens (i.e., those listed in Tables 1 and
2) (Tables 4 and 6). For example, even the
most predictive combination (the combined
results of Trp53+/– for genotoxic chemicals
plus Tg.AC for nongenotoxic chemicals; strat-
egy 7) still had 6 negative results for
IARC/ROC known carcinogens among the
total of 53 chemicals tested in both (Table 6).
In contrast, the NTP two-species bioassay
identified all IARC/NTP known/probable
human carcinogens (Tables 1 and 2). Thus, as
shown in Table 6 (strategy 9), among the 58
chemicals evaluated in the NTP bioassay, there
were no negative results for known human car-
cinogens. However, this is not without a
downside in the form of numerous positive
ﬁndings for chemicals that are considered to be
noncarcinogens in humans (Table 3). In this
data set, there were 18 positive assay results for
IARC/ROC noncarcinogens among a total of
58 chemicals tested, or 31% (Table 6).
Certainly, there is a cost of this type of error as
well, speciﬁcally unneeded regulation and/or
additional testing. It is this propensity for posi-
tive findings for chemicals considered to be
human noncarcinogens that yielded the sur-
prisingly low 69% concordance between the
standard NTP bioassay and human cancer—
surprising because many of the ROC and
IARC determinations are based in large part
on animal data and the NTP bioassay in par-
ticular. In fact, all three transgenic models had
a modestly higher concordance with human
carcinogens (Tables 1 and 2) than the rodent
2-year bioassay (Trp53+/– 81%, RasH2 76%,
and Tg.AC 74%; Table 6). Of course, this dif-
ference is also reﬂected in the modest success
(54–75%) of the transgenic models as predic-
tors of the bioassay response (Table 7).
It should be emphasized that it is possible
that many of the 18 NTP rodent carcinogens
labeled in our analysis as “positive for noncar-
cinogens” (Table 6, strategy 9) may ultimately
prove to be actual human carcinogens as addi-
tional data become available. However, at this
time the positive rodent data are not suffi-
ciently compelling for the IARC or the NTP
ROC to consider these chemicals to be known,
probable, possible, or reasonably anticipated
human carcinogens. In those rare cases where
the IARC and ROC disagreed (e.g., diethyl-
hexyl phthalate) we used the most recent deter-
mination. Moreover, these 18 chemicals
collectively were positive in only 23% (7/30)
of the three transgenic assays evaluated, as
compared with 66% (29/44) positive trans-
genic assays conducted on the 24 known/prob-
able carcinogens. This difference strongly
suggests that the transgenic assays are selec-
tively identifying the trans-species carcinogens.
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Table 6. Summary of performance of each strategy versus likely human cancer when all chemicals in
Table 3 are regarded as true human noncarcinogens. 
Positive for Negative for Positive for Negative for Overall
Strategy carcinogens noncarcinogens noncarcinogens carcinogens accuracy
Trp53+/– 21 27 1 10 81% (48/59)
Trp53+/– (genotoxic) 16 6 0 4 85% (22/26)
Tg.AC 17 29 10 6 74% (44/62)
RasH2 21 18 5 7 76% (39/51)
Trp53+/– (genotoxic); RasH2 (nongenotoxic) 17 18 3 6 80% (35/44)
Trp53+/– (genotoxic); RasH2 (all) 30 14 5 4 83% (44/53)
Trp53+/– (genotoxic); Tg.AC (nongenotoxic) 21 23 3 6 83% (44/53)
Trp53+/– (genotoxic); Tg.AC for all 25 22 10 4 77% (47/61)
NTP rodent bioassay 23 17 18 0 69% (40/58)
NTP rat bioassay; Tg.AC (nongenotoxic); 35 13 9 0 84% (48/57)
Trp53+/– (genotoxic)
NTP rat bioassay; RasH2 (nongenotoxic); 33 12 8 0 85% (45/53)
Trp53+/– (genotoxic)
NTP rat bioassay; genotoxicity 36 7 23 0 65% (43/66)
Deﬁnitions: positive for carcinogens, positive assay results for IARC/ROC carcinogens; negative for noncarcinogens, neg-
ative assay results for IARC/ROC noncarcinogens; positive for noncarcinogens, positive assay results for IARC/ROC non-
carcinogens; negative for carcinogens, negative assay results for IARC/ROC carcinogens. 
Table 7. Summary performance of each strategy (vs. NTP rodent cancer results).
Positive for Negative for Positive for Negative for Overall
Strategy carcinogens noncarcinogens noncarcinogens carcinogens accuracy
Trp53+/– 7 12 0 16 54% (19/35)
Trp53+/– (genotoxic) 7 5 0 4 75% (12/16)
Tg.AC 14 10 2 14 60% (24/40)
RasH2 15 9 0 8 75% (24/32)
Trp53+/– (genotoxic); RasH2 (nongenotoxic) 9 10 0 8 70% (19/27)
Trp53+/– (genotoxic); RasH2 (all) 17 7 0 3 89% (24/27)
Trp53+/– (genotoxic); Tg.AC (nongenotoxic) 10 8 0 14 56% (18/32)
Trp53+/– (genotoxic); Tg.AC for all 16 7 2 13 61% (23/38)
Definitions: positive for carcinogens, positive assay results for NTP rodent carcinogens; negative for noncarcinogens,
negative assay results for NTP rodent noncarcinogens; positive for noncarcinogens, positive assay results for NTP rodent
noncarcinogens; negative for carcinogens, negative assay results for NTP rodent carcinogens. Because both transgenic models and the
bioassay have strengths and weakness in cor-
rectly identifying carcinogenic chemicals, we
examined the performance of composite strate-
gies using both transgenic and conventional
rodent models to determine if such a strategy
might capitalize on the strengths of both types
of models. Strategies 10 and 11 address this
possibility (Table 6). Strategy 10 (rat bioassay
for all chemicals plus the Trp53+/– model for
genotoxic agents or the Tg.AC for nongeno-
toxic chemicals) provided an improvement in
performance. Overall concordance increased to
84% versus the 69% of the bioassay itself.
More important, negative results for known
carcinogens were completely eliminated, and
positive findings for noncarcinogens were
reduced to 16% (9/57) versus the 31%
(18/58) for the bioassay. A similar strategy
(strategy 11) substituting RasH2 for Tg.AC
gave similar results, with an overall concor-
dance of 85% (45/53), or just 15% (8/53)
with positive results for noncarcinogens.
For those chemicals evaluated in both the
NTP bioassay and the transgenic models, the
substitution of the transgenic models (strat-
egy 10: Trp53+/– for genotoxic chemicals;
the Tg.AC for nongenotoxic chemicals) for
the B6C3F1 mouse used in the standard
bioassay resulted in a net reduction of four
positive ﬁndings. Four chemicals (coconut oil
diethanolamine, diethanolamine, N-methylo-
acrylamide, and methylphenidate) were nega-
tive in the transgenic models and the NTP rat
bioassay. In the B6C3F1 mouse, the ﬁrst two
of these chemicals produced liver tumors
(both sexes) and kidney adenomas (males
only). N-Methyloacrylamide produced tumors
of the Harderian gland, liver, lung, and ovary.
Methylphenidate produced liver tumors only.
None of these chemicals has been classiﬁed as
a known/probable human carcinogen by the
IARC or the NTP ROC (Tables 1–3).
Historically, genotoxicity has proven to
be an important clue as to the likely carcino-
genesis of chemicals (Ashby and Tennant
1991; Shelby 1988). In addition, as shown in
Table 4, it increases the predictiveness of the
Trp53+/– model. Thus, to provide a more
complete assessment of possible testing strate-
gies, we compared an additional strategy (strat-
egy 12, Table 6) that consists of substitution of
genotoxicity data for the transgenic models to
be used in concert with the rat bioassay (strate-
gies 10 and 11, Table 6). Strategy 12 does, like
the bioassay itself, avoid negative results for
known carcinogens. It also has modest con-
cordance with human carcinogenesis 65%
(43 of 66), but it has 23 positive results for
noncarcinogens out of 66 chemicals (35%).
A number of the other strategies do better.
Conclusions. Given the complementary
strengths demonstrated by the transgenic mod-
els and the 2-year rodent bioassay as presented
above and summarized in Table 6, it appears
that a strategy employing both types of mod-
els would have advantages over either alone.
Thus, strategies 10 and 11 that use the stan-
dard rat bioassay in conjunction with
Trp53+/– for genotoxic chemicals and Tg.AC
or RasH2 for nongenotoxic chemicals are
promising, based on their performance with
these 99 chemicals.
Research Needs
This analysis demonstrates that transgenic
models have the potential to play an important
role in identiﬁcation of potential human car-
cinogens. However, several research needs and
data gaps remain to be addressed to ensure that
the use of transgenic models has been ade-
quately evaluated and that protocols have been
optimized or standardized for such use, critical
requirements for the regulatory acceptance of
transgenic model data and its use in human
risk assessment.
Validation of study design. The study
design for each transgenic model must be rig-
orously evaluated and optimized for the testing
paradigm used (e.g., toxicity, mutagenicity, or
carcinogenicity). Therefore, additional research
will be required for each model evaluated and
used in the NTP testing program. As men-
tioned previously, the testing strategies, animal
numbers, duration of dosing, extent of pathol-
ogy, and interpretation of results varied among
the studies evaluated. In particular, an optimal
design for transgenic models has not yet been
identiﬁed that clearly eliminates the potential
for false negatives in carcinogen identiﬁcation.
Two possible strategies for increasing the
power of the study (thereby reducing the nega-
tive results for known human carcinogens) are
to increase the sample size beyond the 15 ani-
mals per group commonly used and/or to
increase the duration of the study to allow
more time for tumors to develop. The perfor-
mance of the transgenics under these different
conditions should be thoroughly investigated
and standardized. A perhaps less obvious possi-
bility would be to compile a rigorous historical
control database for the various transgenic
models and to make use of this information in
weight-of-evidence decisions. Many of the tis-
sues in the transgenic mouse models have a
low spontaneous tumor incidence. Thus, the
occurrence of two or three of these tumors in a
dosed group in a given study, although per-
haps not statistically significant when tested
against the concurrent controls, may neverthe-
less be signiﬁcant when the low historical con-
trol incidence is taken into account. For
example, three of the seven negative results for
known/suspected carcinogens associated with
the RasH2 model (cyclosporin A, melphalan,
and 1,4-dioxane) produced tumor effects that
were considered equivocal. Had it been possi-
ble to consider these tumor responses in the
context of a large historical control database,
certain borderline cases might have been
regarded as biologically significant, thereby
reducing the number of incorrect ﬁndings.
Improve understanding of chemical out-
comes. One problem in our analysis was in
identifying a rational basis to explain discor-
dant results. For example, the most signiﬁcant
shortcoming of a combined (transgenic plus
rat bioassay) strategy was not the negative
results for known carcinogens, but rather the
apparent number of positive chemicals in the
rat bioassay that are not listed as known or rea-
sonably anticipated to be human carcinogens
(e.g., the 8 of the 53 chemicals for strategy 11;
Table 6). How might this be improved? First,
it might be possible to design additional stud-
ies to investigate whether or not these are truly
noncarcinogenic chemicals. As discussed
above, the targeted response in our investiga-
tion is imperfect, as it represents a scientific
judgment by IARC and/or the ROC regarding
potential carcinogenicity based on available
data. In many cases, the existing data are insuf-
ficient for a definitive decision to be made.
Additional research could reduce the number
of positive results for supposed noncarcinogens
simply by revealing that certain of these chemi-
cals are in fact carcinogens. Other options that
might be considered to reduce this type of
error include a rat transgenic model (if done
in a manner that did not yield negative results
for known carcinogens) or improvements in
the design of the rat bioassay itself.
Development of a chemical database to
validate transgenics. The data set summarized
in Tables 1–3 may provide an important
resource if appropriate statistical considera-
tions could be developed to allow selection of
an informative subset of chemicals to evaluate
new models and/or modify current protocols.
Such a set of chemicals that represents a spec-
trum of mechanisms or modes of action con-
sistent with human carcinogenesis would not
only be valuable in the context of the models
discussed above but would lend itself to the
evaluation and validation of any new model,
transgenic or otherwise.
Development of models. In the current
analysis we examined the Trp53+/–, Tg.AC,
and RasH2 transgenic models because these
models had the most complete data sets avail-
able. Other models are also under evaluation
at the NIEHS/NTP (p16Ink4a and p19Arf
deﬁcient mice) or elsewhere (XPA-Trp53 deﬁ-
cient mice). A new generation of transgenic
models is also currently being developed
(Berns 2001), such as one incorporating a
point mutation in k-Ras (Johnson et al.
2001), or models subject to premature aging
or having telomere dysfunction (Artandi and
DePinho 2000; Rudolph et al. 2001). If the
NTP incorporates transgenic models into
routine testing, it must necessarily include a
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the transgenic models appropriate for chemi-
cal carcinogenesis investigation and identiﬁca-
tion of carcinogens of the greatest risk to
humans. As our analysis shows, the best strat-
egy for testing may be combining different
transgenic models depending on their partic-
ular attributes and utility. Thus, the NTP
should develop an arsenal of models.
Likewise, site-specific or mechanism-specific
models could be developed and used in both
basic research and carcinogen identification.
The NTP could also develop or support
research to evaluate transgenic rats or in
assessment of possible refinements in the
2-year rat bioassay.
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